Editas Medicine Inc. (NASDAQ: EDIT) is -0.45% lower on its value in year-to-date trading and has touched a low of $7.70 and a high of $21.59 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EDIT stock was last observed hovering at around $8.18 in the last trading session, with the day’s gains setting it 0.65% off its average median price target of $12.00 for the next 12 months. It is also 75.47% off the consensus price target high of $36.00 offered by 19 analysts, but current levels are -26.14% lower than the price target low of $7.00 for the same period.
Currently trading at $8.83, the stock is 3.31% and -9.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.82 million and changing 7.95% at the moment leaves the stock -31.45% off its SMA200. EDIT registered -51.35% loss for a year compared to 6-month loss of -45.99%.
The stock witnessed a -4.02% gain in the last 1 month and extending the period to 3 months gives it a -24.79%, and is 6.00% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.16% over the week and 7.08% over the month.
Editas Medicine Inc. (EDIT) has around 264 employees, a market worth around $589.05M and $25.60M in sales. Distance from 52-week low is 14.60% and -59.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.90%).
Editas Medicine Inc. (EDIT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Editas Medicine Inc. (EDIT) is a “Hold”. 19 analysts offering their recommendations for the stock have an average rating of 2.80, where 11 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 3 analysts have rated the stock as a Sell or Underperform.
Editas Medicine Inc. is expected to release its quarterly report on 05/03/2023.The EPS is expected to shrink by -43.90% this year.
Editas Medicine Inc. (EDIT) Top Institutional Holders
The shares outstanding are 68.74M, and float is at 68.43M with Short Float at 31.64%.
Editas Medicine Inc. (EDIT) Insider Activity
A total of 6 insider transactions have happened at Editas Medicine Inc. (EDIT) in the last six months, with sales accounting for 6 and purchases happening 0 times. The most recent transaction is an insider sale by ROBERTSON MICHELLE,the company’sEVP, CHIEF FINANCIAL OFFICER. SEC filings show that ROBERTSON MICHELLE sold 1,752 shares of the company’s common stock on Jan 10 at a price of $8.16 per share for a total of $14296.0. Following the sale, the insider now owns 80530.0 shares.
Editas Medicine Inc. disclosed in a document filed with the SEC on Dec 05 that Eaton Bruce (EVP, CHIEF BUSINESS OFFICER) sold a total of 102 shares of the company’s common stock. The trade occurred on Dec 05 and was made at $10.23 per share for $1043.0. Following the transaction, the insider now directly holds 64636.0 shares of the EDIT stock.
Still, SEC filings show that on Dec 05, ROBERTSON MICHELLE (EVP, CHIEF FINANCIAL OFFICER) disposed off 193 shares at an average price of $10.23 for $1974.0. The insider now directly holds 82,282 shares of Editas Medicine Inc. (EDIT).
Editas Medicine Inc. (EDIT): Who are the competitors?
The company’s main competitors (and peers) include Molecular Templates Inc. (MTEM) that is trading -83.77% down over the past 12 months.